Page 434 - Feline Cardiology

Generic Name Indications/Drug Dosage and Comments Available sizes
(Brand Name) Type Possible Routes
of Admin.

Procainamide Class Ia anti- 3–8 mg/kg PO Third-choice orally active ventricular 250,375,
(Pronestyl, Procan arrhythmic q 6–8h antiarrhythmic (if sotalol, atenolol ineffective). 500 mg
[H]) 1–2 mg/kg Efficacy poorly studied in cats. Regular Tab
slow IV; formulation preferred over sustained-release, 250,500,
may follow despite increased dosing frequency. Sustained- 750, 1000 mg
with release formulations can be given less often SR Tab
10–20 mcg/kg/ (q 8–12 h) in other species, but also 500 mg/ml
min unpredictably absorbed, including undigested Inj
IV CRI tablet passed intact in feces. Many HM
interactions with other drugs. Increasingly
difficult to obtain due to decreased demand in
human cardiology. IV use for ventricular
tachycardia not responsive to lidocaine, start
at low dose and monitor for significant
hypotension as a common side effect.

PromAce—see
Acepromazine

Pronestyl—see
procainamide
Propantheline Orally active 0.8–1.6 mg/kg Medical treatment for pathologic bradycardias 7.5,
(ProBanthine [H]) vagolytic PO q 8h (i.e., third-degree or high-grade Mobitz type II 15 mg
second-degree AV block; sinus node Tab
dysfunction/sick sinus syndrome; sinus HM
bradycardia) when underlying cause is
optimally controlled. This medication usually
is ineffective in cats with these
bradyarrhythmias but it may be administered
as an attempt to noninvasively treat the
arrhythmias. Signs of parasympathetic excess
(notably constipation) are dose-limiting.
Pacemaker implantation becomes necessary if
severe clinical signs caused by bradycardia
are apparent.
Continued

459 Drug Formulary